DelveInsight has launched a new report on “Prader-Willi Syndrome – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Prader-Willi Syndrome – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts:
- Prader-Willi Syndrome occurs in approximately one out of every 15,000 births.
- It affects males and females with equal frequency and affects all races and ethnicities
- According to DelveInsight’s estimation, the total prevalent cases of Prader Willi syndrome (PWS) were found to be ~47,000 for 7 Major Markets in the year 2017
- The Prader-Willi Syndrome Association (PWSA) estimates that the prevalence of PWS is approximately 1 in 12-15,000 people in the US. Using the more conservative estimate, this translates into a target population of approximately 22,000 at present which is quite low.
Request for free sample: https://www.delveinsight.com/sample-request/prader-willi-syndrome-market
Scope of the Report
- The report covers the descriptive overview of Prader-Willi Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Prader-Willi Syndrome epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Prader-Willi Syndrome are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Prader-Willi Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Prader-Willi Syndrome market.
Prader-Willi syndrome is a complex genetic condition that affects many parts of the body. In infancy, this condition is characterized by weak muscle tone (hypotonia), feeding difficulties, poor growth, and delayed development. Beginning in childhood, affected individuals develop an insatiable appetite, which leads to chronic overeating (hyperphagia) and obesity. Some people with Prader-Willi syndrome, particularly those with obesity, also develop type 2 diabetes (the most common form of diabetes).
The disease occurs due to the loss of function of several genes in a particular region of chromosome number 15. Among these are genes that provide instructions for making molecules called small nucleolar RNAs (snoRNAs).
According to NORD, Prader-Will Syndrome (PWS) is the first syndromic form of neurodevelopmental disorder that was confirmed to be caused due to imprinting errors leading to a genetic multisystem disorder characterized during infancy by lethargy, diminished muscle tone (hypotonia), feeding difficulties, poor weight gain and growth hormone deficiency.
Although considered a “rare” disorder, PWS is one of the most common conditions seen in genetic clinics and is the most common genetic cause of obesity that has been identified to date.
Request for free sample: https://www.delveinsight.com/sample-request/prader-willi-syndrome-market
Key Companies Covered:
- Soleno Therapeutics Inc.
- Levo Therapeutics
- Millendo Therapeutics
- Harmony Biosciences
- And Many Others
Drugs Covered:
- Diazoxide Choline Controlled-Release (DCCR)
- LV-101
- Livoletide or AZP-531
- Pitolisant
- And Many Others
Request for free sample: https://www.delveinsight.com/sample-request/prader-willi-syndrome-market
Table of Contents:
1. Key Insights
2. Executive Summary of Prader-Willi Syndrome
3. Competitive Intelligence Analysis for Prader-Willi Syndrome
4. Prader-Willi Syndrome: Market Overview at a Glance
4.1. Prader-Willi Syndrome Total Market Share (%) Distribution in 2017
4.2. Prader-Willi Syndrome Total Market Share (%) Distribution in 2030
5. Prader-Willi Syndrome: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Prader-Willi Syndrome Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Prader-Willi Syndrome Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Prader-Willi Syndrome Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Prader-Willi Syndrome Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Prader-Willi Syndrome Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Prader-Willi Syndrome Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Prader-Willi Syndrome Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Prader-Willi Syndrome Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Prader-Willi Syndrome Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Prader-Willi Syndrome Treatment and Management
8.2. Prader-Willi Syndrome Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Prader-Willi Syndrome Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Prader-Willi Syndrome: Seven Major Market Analysis
13.1. Key Findings
13.2. Prader-Willi Syndrome Market Size in 7MM
13.3. Prader-Willi Syndrome Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Prader-Willi Syndrome Total Market Size in the United States
15.1.2. Prader-Willi Syndrome Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Prader-Willi Syndrome Total Market Size in Germany
15.3.2. Prader-Willi Syndrome Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Prader-Willi Syndrome Total Market Size in France
15.4.2. Prader-Willi Syndrome Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Prader-Willi Syndrome Total Market Size in Italy
15.5.2. Prader-Willi Syndrome Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Prader-Willi Syndrome Total Market Size in Spain
15.6.2. Prader-Willi Syndrome Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Prader-Willi Syndrome Total Market Size in the United Kingdom
15.7.2. Prader-Willi Syndrome Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Prader-Willi Syndrome Total Market Size in Japan
15.8.3. Prader-Willi Syndrome Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Prader-Willi Syndrome
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/prader-willi-syndrome-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/prader-willi-syndrome-market